Luccioni R, Lambert M, Ambrosi P, Scemama M
Department of Cardiology, CHU la Timone, Marseille, France.
Eur J Clin Pharmacol. 1993;45(2):157-60. doi: 10.1007/BF00315498.
The antihypertensive efficacy and acceptability of 3 doses of rilmenidine (0.5, 1 and 2 mg, once daily) and a placebo over a 4 week period have been compared in a randomised, double-blind, parallel-group trial in 60 mild to moderate hypertensive patients. Six patients dropped out: 4 in the 2 mg-group and one in the 1 mg-group because of adverse events, and one in the placebo group for personal reason. The blood pressure was significantly decreased after the 1 and 2 mg doses with the maximum antihypertensive effect already being obtained after 1 mg. A significant dose-effect relationship was shown for supine systolic blood pressure (P = 0.05) but not for the supine diastolic blood pressure. The most beneficial efficacy/acceptability ratio was achieved at the dose of 1 mg once daily, which demonstrated the maximum antihypertensive effect associated with a low incidence of adverse events.
在一项针对60例轻至中度高血压患者的随机、双盲、平行组试验中，比较了3种剂量（0.5、1和2毫克，每日一次）的利美尼定和安慰剂在4周内的降压疗效及可接受性。6例患者退出：2毫克组有4例，1毫克组有1例因不良事件退出，安慰剂组有1例因个人原因退出。1毫克和2毫克剂量用药后血压显著下降，1毫克剂量用药后已达到最大降压效果。仰卧位收缩压显示出显著的剂量-效应关系（P = 0.05），但仰卧位舒张压未显示出该关系。每日一次1毫克剂量时疗效/可接受性比最有益，该剂量显示出最大降压效果且不良事件发生率较低。
